Real-World Evidence: What Can You Say to Payers and Patient Advocates?
This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.
This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.
ChatGPT is disrupting content creation, from term papers to journal articles to online information mills and more. This webinar gathers three thought leaders at the cutting edge of this issue to vision how ChatGPT may augment or, at times, undermine the practice of Medical Affairs in areas such as Medical Information, Omnichannel engagement and more.
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future.
This Webinar series explores how roles and talent management have evolved, what new roles exist or are needed and what skills and competencies are required to succeed in these roles. From the manager’s perspective, we will discuss potential strategies for staying on top of this ever-changing field to manage and retain highly effective teams.
This White Paper provides a foundational understanding of insights management, including the definition and value of insights, processes and technologies for insights management, and key challenges in implementation.
This webinar provides multiple perspectives from both both industry and agency partners, examining how to ensure alignment on needs, goals, and mutual accountability, as well as defining what a “best” partner looks like.
This presentation looks at different regulatory contexts in which product developers are using RWE.
This virtual presentation focuses on 3 aspects of RWE: What are RWE and Real-World Data (RWD), and how are they different? What are relevant legal and regulatory considerations associated with using RWE for product label expansion? How have applicants successfully used RWE to obtain approval for new drug and medical device indications?
This webinar seeks to help Medical Affairs professionals better understand the business of life science companies, how their efforts impact the overall capability to commercialize a product, and contemporary ways to bridge the commercialization interface between their department and Marketing & Sales.
This Webinar aims to achieve awareness on challenges and solutions when listening to, and interacting with, Digital Opinion Leaders.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.